AU550774B2 - 1-aryl-2-aminomethyl cyclopropane carboxylates - Google Patents

1-aryl-2-aminomethyl cyclopropane carboxylates

Info

Publication number
AU550774B2
AU550774B2 AU85086/82A AU8508682A AU550774B2 AU 550774 B2 AU550774 B2 AU 550774B2 AU 85086/82 A AU85086/82 A AU 85086/82A AU 8508682 A AU8508682 A AU 8508682A AU 550774 B2 AU550774 B2 AU 550774B2
Authority
AU
Australia
Prior art keywords
cyclopropane
hydrochloride
phenyl
general formula
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU85086/82A
Other languages
English (en)
Other versions
AU8508682A (en
Inventor
Bernard Bonnaud
Henri Cousse
Michel Morre
Gilbert Mouzin
Antoine Stenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU550774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Publication of AU8508682A publication Critical patent/AU8508682A/en
Application granted granted Critical
Publication of AU550774B2 publication Critical patent/AU550774B2/en
Assigned to PIERRE FABRE S.A. reassignment PIERRE FABRE S.A. Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Assigned to PIERRE FABRE MEDICAMENT reassignment PIERRE FABRE MEDICAMENT Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU85086/82A 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates Expired AU550774B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8112312 1981-06-23
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central

Publications (2)

Publication Number Publication Date
AU8508682A AU8508682A (en) 1983-01-06
AU550774B2 true AU550774B2 (en) 1986-04-10

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85086/82A Expired AU550774B2 (en) 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates

Country Status (11)

Country Link
US (1) US4478836A (enExample)
EP (1) EP0068999B1 (enExample)
JP (1) JPS584752A (enExample)
AT (1) ATE13422T1 (enExample)
AU (1) AU550774B2 (enExample)
CA (1) CA1202639A (enExample)
DE (1) DE3263734D1 (enExample)
ES (1) ES8303293A1 (enExample)
FR (1) FR2508035A1 (enExample)
LU (1) LU90410I2 (enExample)
ZA (1) ZA824453B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
JP4288263B2 (ja) * 2002-10-25 2009-07-01 コレジウム ファーマシューティカル， インク． ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
NZ541733A (en) 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
EP1656349B1 (en) 2003-08-15 2011-10-12 H. Lundbeck A/S Cyclopropyl derivatives as nk3 receptor antagonists
AR045368A1 (es) * 2003-08-15 2005-10-26 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
JP4418717B2 (ja) * 2004-06-24 2010-02-24 住友化学株式会社 （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TW200718692A (en) * 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
EP1894565B1 (en) 2005-06-10 2013-10-30 Pierre Fabre Médicament S.A. Stabilized milnacipran formulation
WO2007008758A2 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR20080091261A (ko) * 2006-01-27 2008-10-09 아사히 가세이 파마 가부시키가이샤 경비 투여용 약제
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2114868A2 (en) * 2007-02-28 2009-11-11 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
MX2012001393A (es) 2009-08-05 2012-08-03 Lupin Ltd Composiciones farmacéuticas de liberación controlada de milnacipran.
JP2013510176A (ja) * 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
WO2012145234A2 (en) * 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
IN2013MU03122A (enExample) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
GB1415541A (en) 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
DE3263734D1 (en) 1985-06-27
FR2508035B1 (enExample) 1984-06-29
EP0068999A1 (fr) 1983-01-05
ATE13422T1 (de) 1985-06-15
JPS584752A (ja) 1983-01-11
CA1202639A (fr) 1986-04-01
FR2508035A1 (fr) 1982-12-24
LU90410I2 (fr) 1999-08-31
ZA824453B (en) 1983-04-27
US4478836A (en) 1984-10-23
JPS6323186B2 (enExample) 1988-05-16
ES512842A0 (es) 1983-03-01
AU8508682A (en) 1983-01-06
EP0068999B1 (fr) 1985-05-22
ES8303293A1 (es) 1983-03-01

Similar Documents

Publication Publication Date Title
AU8508682A (en) 1-aryl-2-aminomethyl cyclopropane carboxylates
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
DE3069408D1 (en) 5-oxo- and 5-thioxoproline derivatives, process for their production and pharmaceutical compositions containing them
ES8103744A1 (es) Un metodo para la preparacion de derivados de ftalimidina
PT76450B (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
BR8906791A (pt) Composicao inseticida; derivado de guanidina e processo para sua preparacao
ES538418A0 (es) Un derivado de indol-3-carboxamida
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
DE3882438D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
ATE132861T1 (de) Derivate von hexahydroazepine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
AU579869B2 (en) 4-amino-8-alkylthio-2-piperazino-pyrimido ``5,4-d`` pyrimidines
PT93450A (pt) Processo para a preparacao de novos derivados azetidinicos de acidos piridinocarboxilicos e de composicoes farmaceuticas que os contem
ES8301460A1 (es) Un procedimiento para la preparacion de l-amino acidos n-sustituidos.
DK469285D0 (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
HUT38948A (en) Process for preparing new isoxazolo-quinolinone derivatives and pharmaceutical compositions containing such compounds
ES8307798A1 (es) Un procedimiento para la preparacion de derivados de piperazilmetil-4-dibenzofuranona, o, dibenzofuranol.
IL70558A (en) 1-(aminoalkoxyphenyl)-1-phenylpropanols,their preparation and pharmaceutical compositions containing them
AU1621392A (en) New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired